R 348 - Rigel
Rigel: Investor Day (Rigel) - May 10, 2014 - Anticipated P2 trial completion for dry eye disease in Q3 2014; Anticipated P2 trial completion for ocular GvHD in Q2 2016 
Anticipated trial completion date • Immunology
http://ir.rigel.com/phoenix.zhtml?p=irol-eventDetails&c=120936&eventID=5144677
 
May 10, 2014
 
.
 
e7153415-ebe1-4915-a60e-7a1de83c08e8.jpg